Form 4: Director Madhavan Balachandran Reports uniQure Equity Moves

Director Madhavan Balachandran acquired restricted share units and stock options while selling shares to cover tax obligations.

Summary

• Director Madhavan Balachandran was granted 7,550 restricted share units (RSUs) on June 10, 2026.
• The Director received 13,980 stock options with an exercise price of $26.82 on June 10, 2026.
• A total of 1,993 shares were sold on June 11, 2026, at a weighted average price of $27.06 to satisfy tax withholding requirements.
• Following these transactions, the Director holds 43,254 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director equity compensation and tax compliance.

Positives

• Director maintains a significant equity stake of 43,254 shares, aligning interests with shareholders.
• The sale of shares was non-discretionary, executed solely to cover tax obligations related to RSU vesting.

Negatives

• None identified; the transactions are standard equity compensation and tax-related activity.

Risks

• Vesting of equity awards is contingent upon the Director's continued relationship with the issuer.

Future Outlook

The equity grants vest 100% on the first anniversary of the grant date, contingent upon the Director's continued service.

Industry Context

StockSavvy.ai notes that this filing reflects standard corporate governance and executive compensation practices within the biotechnology sector, where equity-based incentives are common for retaining board members.

Comparison to Industry Standards

• The use of automatic sell-to-cover transactions for tax obligations is a standard practice among publicly traded biotech firms to manage executive tax liabilities.
• The vesting schedule of one year for director equity is consistent with typical industry governance standards.

Stakeholder Impact

• Minimal impact; the transactions represent standard compensation and tax management by a director.

Next Steps

• Vesting of restricted share units on June 10, 2027.
• Vesting of stock options on June 10, 2027.

Key Dates

Keywords

uniQure, QURE, Form 4, Insider Trading, Equity Compensation, Biotech